Research Analysts’ Recent Ratings Changes for Ventas (VTR)

Several analysts have recently updated their ratings and price targets for Ventas (NYSE: VTR):

• 6/24/2026 – Ventas had its “buy (b-)” rating reaffirmed by Weiss Ratings.
• 6/18/2026 – Ventas had its price target lowered by Scotiabank from $95.00 to $88.00. They now have a “sector perform” rating on the stock.
• 6/16/2026 – Ventas is now covered by Raymond James Financial, Inc.. They set an “outperform” rating and a $94.00 price target on the stock.
• 6/16/2026 – Ventas had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $100.00 price target on the stock.
• 6/16/2026 – Ventas was upgraded by Raymond James Financial, Inc. to “moderate buy”.
• 6/1/2026 – Ventas had its price target raised by Wells Fargo & Company from $93.00 to $96.00. They now have an “overweight” rating on the stock.
• 5/22/2026 – Ventas was given a new $98.00 price target by Mizuho.
• 5/21/2026 – Ventas had its price target raised by Scotiabank from $93.00 to $95.00. They now have a “sector perform” rating on the stock.
• 5/19/2026 – Ventas had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $110.00 price target on the stock.
• 5/12/2026 – Ventas had its price target raised by Jefferies Financial Group Inc. from $97.00 to $100.00. They now have a “buy” rating on the stock.
• 5/11/2026 – Ventas had its price target raised by JPMorgan Chase & Co. from $93.00 to $94.00. They now have an “overweight” rating on the stock.
• 5/7/2026 – Ventas had its price target raised by KeyCorp from $90.00 to $95.00. They now have an “overweight” rating on the stock.
• 5/4/2026 – Ventas had its “outperform” rating reaffirmed by BMO Capital Markets. They now have a $100.00 price target on the stock.
• 5/4/2026 – Ventas had its price target raised by Royal Bank Of Canada from $91.00 to $98.00. They now have an “outperform” rating on the stock.
• 5/4/2026 – Ventas had its price target raised by UBS Group AG from $85.00 to $93.00. They now have a “neutral” rating on the stock.
• 5/1/2026 – Ventas had its price target raised by Citigroup Inc. from $96.00 to $100.00. They now have a “buy” rating on the stock.

Ventas Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 16th. Shareholders of record on Tuesday, June 30th will be issued a $0.52 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.4%. Ventas’s dividend payout ratio (DPR) is currently 378.18%.

Insiders Place Their Bets

In related news, Director Michael J. Embler acquired 2,500 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was acquired at an average cost of $78.81 per share, for a total transaction of $197,025.00. Following the completion of the purchase, the director owned 19,202 shares of the company’s stock, valued at approximately $1,513,309.62. This represents a 14.97% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Walter C. Rakowich sold 1,152 shares of the business’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $90.20, for a total transaction of $103,910.40. Following the sale, the director directly owned 28,349 shares in the company, valued at $2,557,079.80. This trade represents a 3.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.53% of the company’s stock.

Ventas, Inc (NYSE: VTR) is a real estate investment trust (REIT) that specializes in healthcare-related real estate. The company acquires, owns and manages a diversified portfolio of properties serving the healthcare continuum, including senior housing communities, skilled nursing facilities, medical office buildings, life science and research centers, and other properties leased to healthcare providers and operators. Ventas generates revenue through long-term leases, property management and selective development activities focused on meeting the real estate needs of the healthcare sector.

Ventas’ business model combines property ownership with active asset management and capital markets activity.